LIXTE Holds the World’s Only Clinical-Stage PP2A Inhibitor
Unlocking a New Era in Cancer Treatment
DENVER, Colo., Sep 05, 2025 (247marketnews.com)- LIXTE Biotechnology’s (NASDAQ:LIXT), a clinical-stage biotechnology company developing first-in-class inhibitors targeting protein phosphatases to enhance cancer treatment, lead compound, LB-100, is the world’s only clinical-stage inhibitor of protein phosphatase 2A (PP2A). This unique “off switch” mechanism positions LB-100 as a next-generation “cancer power-up” capable of transforming how traditional therapies work against solid tumors.
LB-100: A First-in-Class Molecule with Multi-Therapy Synergy
LB-100 represents a first-in-class PP2A inhibitor, with a distinctive ability to disrupt cancer’s internal repair systems and push cells into “lethal activation.” By inhibiting PP2A, LB-100 both stimulates cancer cell activity to self-destructive levels and generates neoantigens, making tumors more visible to the immune system.
Unlike traditional therapies that only kill cancer cells directly, LB-100 sensitizes tumors to immunotherapy, chemotherapy, and radiation by exposing hidden tumors and amplifying immune response.
PP2A: A Master Switch in Tumor Defense
PP2A is a key cellular enzyme regulating DNA damage repair, cell cycle progression, and survival signaling. Many cancers exploit PP2A as an “emergency off switch” to evade treatment. LB-100 disables this switch, stripping cancer cells of their defense and preventing recovery from therapy-induced stress.
This ability to break resistance barriers is particularly critical in MSS colorectal cancer (85% of cases) and ovarian clear-cell carcinoma, where current immunotherapy options are largely ineffective.
Delivering Broader Impact
One of LB-100’s most promising features is its ability to improve the impact of existing therapies at optimized doses, resulting in:
- Enhanced activity of standard treatments
- Stronger immune engagement
- A favorable combination profile
By improving both tolerability and efficacy, LB-100 has the potential to reshape treatment standards across multiple solid tumor indications.
Current Trials and Strategic Collaborations
LB-100 is currently being evaluated in multiple clinical programs, including:
- Ovarian Clear-Cell Carcinoma (GSK Partnership): In collaboration with GSK (NYSE:GSK), which is providing Dostarlimab and full trial funding.
- MSS Colorectal Cancer (Roche Partnership): Conducted in collaboration with Roche (OTCQX:RHHBY), which is providing atezolizumab and full trial funding, at the Netherlands Cancer Institute. Enrollment is under a temporary voluntary safety pause following early adverse events.
- Soft-Tissue Sarcoma: Phase 1 completed successfully with no toxicity concerns. Phase 2 has been discontinued to prioritize immunotherapy combination programs with higher commercial potential.
These studies are designed not only to validate LB-100’s safety and efficacy but also to demonstrate its unique role as a universal enhancer of frontline cancer therapies.
About LIXTE Biotechnology Holdings, Inc.
LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company’s lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.
More information can be found at: www.lixte.com
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com